Long-term Outcome of Invasive Staphylococcus Aureus Infections
Overview
Authors
Affiliations
Background: Short-term mortality from invasive Staphylococcus aureus infections (ISA) is high. Death rates from 20% to 60% are reported. Long-term outcome has not been investigated. Studies of other critical illnesses have demonstrated incremental health effects that persist after hospital discharge. Several researchers have proposed that evaluation of mortality secondary to sepsis should take place after 1 y.
Methods: We performed an observational, prospective, population-based study of long-term mortality and recurrence in a cohort of ISA patients during 2 y.
Results: One hundred and fifty-seven patients were included. All-cause mortality after 1 y was 37.6% and after 3 y was 45.5%. The multivariate survival analysis explored different independent factors for short-term compared to long-term mortality. Age, comorbidity, and place of acquisition were the determinants of long-term outcome. In contrast, infection-related factors such as disease severity and systolic blood pressure determined short-term mortality. The relapse-reinfection rate was 11.2% (16 in 143 episodes in 127 patients living 4 weeks after inclusion). Predictive factors for relapse-reinfection in a univariate analysis were joint prosthesis (28.6%, p = 0.027), haemodialysis (27.8%, p = 0.017), kidney disease (22.2%, p = 0.015), and healthcare- and nosocomial-related infection (18.3%, p = 0.029). No association to length of antibiotic therapy and relapse-reinfection rate was observed, nor any sex differences. The majority of relapses-reinfections (11 of 16) occurred during the first 11 months after the initial episode.
Conclusion: Patients with ISA infections, irrespective of age, suffer a high long-term mortality and recurrence rate.
Legg A, Roberts M, Davies J, Cass A, Meagher N, Sud A Open Forum Infect Dis. 2023; 10(7):ofad337.
PMID: 37496601 PMC: 10368200. DOI: 10.1093/ofid/ofad337.
A structure activity relationship study of 3,4'-dimethoxyflavone for ArlRS inhibition in .
Weig A, OConner P, Kwiecinski J, Marciano O, Nunag A, Gutierrez A Org Biomol Chem. 2023; 21(16):3373-3380.
PMID: 37013457 PMC: 10192164. DOI: 10.1039/d3ob00123g.
Increasing Pediatric Infectious Diseases Consultation Rates for Bacteremia.
Gordon O, Akindele N, Schumacher C, Hanlon A, Simner P, Carroll K Pediatr Qual Saf. 2022; 7(3):e560.
PMID: 35720864 PMC: 9197366. DOI: 10.1097/pq9.0000000000000560.
Forsblom E, Frilander H, Ruotsalainen E, Jarvinen A Open Forum Infect Dis. 2020; 6(12):ofz495.
PMID: 32128337 PMC: 7047950. DOI: 10.1093/ofid/ofz495.
Kwiecinski J, Crosby H, Valotteau C, Hippensteel J, Nayak M, Chauhan A PLoS Pathog. 2019; 15(5):e1007800.
PMID: 31116795 PMC: 6548404. DOI: 10.1371/journal.ppat.1007800.